Locke Lord Represents Juvenescence in Purchase of 14.4 Million Shares of AgeX Therapeutics

A Locke Lord team led by Eugene McDermott and Douglas Gray (both of Providence), represented Juvenescence Limited, a leading drug development company based in the British Virgin Islands, focused on the development of therapies to increase human longevity, in its purchase of 14.4 million shares of AgeX Therapeutics, Inc. for $43.2 million, from its affiliate BioTime, Inc. (NYSE American: BTX). AgeX is focused on developing novel therapeutics for age-related degenerative disease. Additional team members included Ralph Loren (Boston), Jason Ulezalka (New York) and Stephen Murphy (Washington, D.C.).
Posted on November 1, 2018